ALPI抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Western blot analysis using ALPI mouse mAb against HL60 (1) and HepG2 (2) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of HepG2 cells using ALPI mouse mAb (green) and negative control (purple).    

  
  

ALPI (alkaline phosphatase, intestinal) antibodies target the intestinal isoform of alkaline phosphatase, an enzyme critical for maintaining gut homeostasis and modulating inflammatory responses. Primarily expressed in the small intestine, ALPI plays a key role in detoxifying bacterial lipopolysaccharides (LPS) by dephosphorylating them, thereby reducing systemic inflammation and protecting intestinal barrier integrity. Dysregulation of ALPI activity has been implicated in inflammatory bowel diseases (IBD), such as Crohn’s disease and ulcerative colitis, as well as metabolic disorders like obesity and diabetes.

Research on ALPI antibodies has focused on their diagnostic and therapeutic potential. In autoimmune or inflammatory conditions, anti-ALPI autoantibodies may serve as biomarkers to assess disease progression or mucosal damage. Conversely, therapeutic strategies using exogenous ALPI or monoclonal antibodies to modulate its activity are being explored. For instance, recombinant ALPI has shown promise in preclinical models for mitigating sepsis and colitis by neutralizing LPS. However, the precise mechanisms linking ALPI dysfunction to specific pathologies remain under investigation, particularly its interplay with gut microbiota and immune signaling pathways. Current challenges include optimizing antibody specificity and delivery methods for clinical applications. ALPI-targeted therapies represent a growing area of interest in gastroenterology and immunology, bridging microbial interactions and host immunity.